Remove 2021 Remove Competition Remove Prescription
article thumbnail

Can we get healthcare right?

World of DTC Marketing

According to The Hill “, a large majority of the public favors allowing the government to negotiate for lower prescription drug prices, according to a new poll that comes as a legislative battle plays out on the issue. These hospitals spent $116 million on federal lobbying in 2021. Innovation and Competition Act.

article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend. As the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

However, patient uptake hasn’t matched rising market competition. As a top patient resource for trusted information, it’s essential that doctors are made aware of the range of prescription migraine therapies and encouraged to recommend them to their patients.

article thumbnail

7 Pharmaceutical Industry Trends for your 2021 Marketing Strategy

Silver Line CRM

Reading time: 7 minutes As we all look to 2021, what are the pharmaceutical industry trends to build into your life sciences marketing strategy? But today, the need to satisfy patients, providers, payers, regulatory agencies, and shareholders alike — while staying ahead of the competition — takes the right technologies at the right time. .

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. Three pending bills introduced in 2021 include strategies for reducing delay caused by Citizen Petitions. Senate Bill 562 (S.

article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

billion in 2021 to £1.8 Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.” “The NHS runs on generic and biosimilar medicines, with four out of five prescriptions being filled by off-patent products,” said the BGMA’s CEO Mark Samuels.

Pharma 72
article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. biologics market and reduce prescription drug costs. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. from 91% in 2023 to 36% by 2031.